Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in AlloSCT Conditioning (VICTORY)
NCT05005299Phase 1Recruiting
- Sponsor
- Melbourne Health
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 3 more (4 arms), sponsored by Melbourne Health. Primary endpoint: Dose-Limiting Toxicities. Started Jun 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05005299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005299.